Quazinone: Difference between revisions
CSV import |
CSV import |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|A cardiotonic agent}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477241679 | |||
| IUPAC_name = 3-(2-((4,5-dihydro-1H-imidazol-2-yl)imino)hydrazinyl)-3-oxopropanenitrile | |||
| image = Quazinone.svg | |||
| image_size = 200px | |||
| image_alt = Structural formula of Quazinone | |||
}} | |||
'''Quazinone''' is a [[pharmaceutical drug]] that acts as a [[cardiotonic agent]]. It is primarily used in the management of certain types of [[heart failure]]. Quazinone belongs to a class of drugs known as [[phosphodiesterase inhibitors]], which work by increasing the force of contraction of the heart muscle, thereby improving cardiac output. | |||
Quazinone is a | |||
== | ==Mechanism of Action== | ||
Quazinone functions by inhibiting the enzyme [[phosphodiesterase]], specifically targeting the type III isoform. This inhibition leads to an increase in intracellular [[cyclic adenosine monophosphate]] (cAMP) levels. Elevated cAMP enhances calcium influx into cardiac cells, which strengthens myocardial contraction and improves the heart's pumping efficiency. This mechanism is particularly beneficial in conditions where the heart's ability to pump blood is compromised. | |||
== | ==Clinical Uses== | ||
Quazinone | Quazinone is used in the treatment of acute [[heart failure]] and other conditions where enhanced cardiac output is necessary. It is often administered in a hospital setting under careful monitoring due to its potent effects and potential side effects. | ||
== | ==Side Effects== | ||
The use of Quazinone can lead to several side effects, primarily due to its action on the heart and vascular system. Common side effects include: | |||
* [[Arrhythmia]] | |||
* [[Hypotension]] | |||
* [[Headache]] | |||
* [[Nausea]] | |||
Due to these potential adverse effects, the use of Quazinone is typically reserved for cases where the benefits outweigh the risks, and alternative treatments are not suitable. | |||
==Pharmacokinetics== | |||
Quazinone is administered intravenously, allowing for rapid onset of action. The drug is metabolized in the liver and excreted primarily through the kidneys. Its pharmacokinetic profile necessitates careful dosing and monitoring, especially in patients with renal or hepatic impairment. | |||
==Related Compounds== | |||
Quazinone is related to other [[phosphodiesterase inhibitors]] such as [[milrinone]] and [[inamrinone]], which are also used in the management of heart failure. These compounds share a similar mechanism of action but may differ in their pharmacokinetic properties and side effect profiles. | |||
==Research and Development== | |||
Research into Quazinone and related compounds continues, with studies focusing on optimizing their efficacy and safety profiles. Investigations into new formulations and delivery methods aim to enhance patient outcomes and reduce adverse effects. | |||
==Related Pages== | |||
* [[Heart failure]] | |||
* [[Phosphodiesterase inhibitor]] | |||
* [[Cardiotonic agent]] | |||
* [[Milrinone]] | |||
* [[Inamrinone]] | |||
[[Category:Cardiotonic agents]] | |||
[[Category:Phosphodiesterase inhibitors]] | |||
Latest revision as of 11:00, 23 March 2025
A cardiotonic agent
| Quazinone | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Quazinone is a pharmaceutical drug that acts as a cardiotonic agent. It is primarily used in the management of certain types of heart failure. Quazinone belongs to a class of drugs known as phosphodiesterase inhibitors, which work by increasing the force of contraction of the heart muscle, thereby improving cardiac output.
Mechanism of Action[edit]
Quazinone functions by inhibiting the enzyme phosphodiesterase, specifically targeting the type III isoform. This inhibition leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP enhances calcium influx into cardiac cells, which strengthens myocardial contraction and improves the heart's pumping efficiency. This mechanism is particularly beneficial in conditions where the heart's ability to pump blood is compromised.
Clinical Uses[edit]
Quazinone is used in the treatment of acute heart failure and other conditions where enhanced cardiac output is necessary. It is often administered in a hospital setting under careful monitoring due to its potent effects and potential side effects.
Side Effects[edit]
The use of Quazinone can lead to several side effects, primarily due to its action on the heart and vascular system. Common side effects include:
Due to these potential adverse effects, the use of Quazinone is typically reserved for cases where the benefits outweigh the risks, and alternative treatments are not suitable.
Pharmacokinetics[edit]
Quazinone is administered intravenously, allowing for rapid onset of action. The drug is metabolized in the liver and excreted primarily through the kidneys. Its pharmacokinetic profile necessitates careful dosing and monitoring, especially in patients with renal or hepatic impairment.
Related Compounds[edit]
Quazinone is related to other phosphodiesterase inhibitors such as milrinone and inamrinone, which are also used in the management of heart failure. These compounds share a similar mechanism of action but may differ in their pharmacokinetic properties and side effect profiles.
Research and Development[edit]
Research into Quazinone and related compounds continues, with studies focusing on optimizing their efficacy and safety profiles. Investigations into new formulations and delivery methods aim to enhance patient outcomes and reduce adverse effects.
